Översikt pipeline

Asset
Indication
Preclinical
Phase I
Phase IIa
Phase IIb
Phase III
Next milestone
AP1189
Rheumatoid Arthritis
top-line results end Nov’21
Nephrotic Syndrome
programme being re-designed, results in 2022
COVID-19-induced acute respiratory distress syndrome
path towards Emergency Approval in exploration
Next target indication
Pharmacology program